Eli Lilly and Company (NYSE:LLY – Get Free Report) EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eli Lilly and Company Trading Up 3.7%
Eli Lilly and Company stock traded up $43.95 during trading hours on Tuesday, reaching $1,227.11. The stock had a trading volume of 2,449,913 shares, compared to its average volume of 3,103,126. The company has a fifty day simple moving average of $1,171.52 and a 200-day simple moving average of $1,053.72. Eli Lilly and Company has a 52 week low of $685.15 and a 52 week high of $1,249.45. The stock has a market cap of $1.16 trillion, a PE ratio of 41.18, a PEG ratio of 1.39 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
Institutional Trading of Eli Lilly and Company
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Iams Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $754,000. Generali Investments Management Co LLC boosted its stake in shares of Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after buying an additional 1,521 shares during the last quarter. Amundi grew its holdings in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock worth $4,649,464,000 after acquiring an additional 454,549 shares during the period. Whitener Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 79.3% in the second quarter. Whitener Capital Management Inc. now owns 2,960 shares of the company’s stock worth $3,550,000 after acquiring an additional 1,309 shares during the period. Finally, May Hill Capital LLC increased its position in Eli Lilly and Company by 131.6% during the fourth quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock valued at $3,408,000 after acquiring an additional 1,801 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have commented on LLY shares. BMO Capital Markets restated an “outperform” rating and issued a $1,400.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 6th. Jefferies Financial Group boosted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. Morgan Stanley restated an “overweight” rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.
Read Our Latest Stock Analysis on LLY
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Obesity-pill momentum: Lilly is reportedly narrowing Novo Nordisk’s early lead in the oral weight-loss market. Investor enthusiasm is being supported by expectations that Lilly’s obesity portfolio can extend its leadership beyond injectable GLP-1 treatments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
- Positive Sentiment: Retatrutide progress: Positive trial developments for retatrutide, Lilly’s next-generation obesity and metabolic-disease candidate, have prompted the company to lift related guidance. The drug could strengthen Lilly’s long-term growth outlook if late-stage results and regulatory progress remain favorable. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
- Positive Sentiment: Pipeline expansion through licensing: Lilly entered a global collaboration with OmniAb for an ion-channel discovery program. The agreement, which includes potential milestone payments of up to $370 million, adds another avenue for future drug development and demonstrates continued investment in external innovation. OmniAb Enters Global Collaboration and License Agreement With Eli Lilly
- Positive Sentiment: CNS pipeline transaction: Lilly paid AlzeCure a $10 million upfront amount in an initial transaction involving small-molecule candidates for Alzheimer’s disease and pain, broadening Lilly’s pipeline beyond its core diabetes and obesity franchises. AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction With Lilly
- Neutral Sentiment: Lilly appointed Tayllit Aherdan to oversee operations in the United Arab Emirates, Qatar and Kuwait. The move supports regional execution but is unlikely to materially affect near-term earnings. Lilly Appoints Tayllit Aherdan
- Negative Sentiment: Analysts continue to flag Lilly’s elevated valuation, competition from Novo Nordisk and other obesity-drug developers, and potential pricing and patent pressures. With shares having already delivered substantial long-term gains, strong future growth may be required to justify additional upside. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
